Biomarin Pharmaceutical Inc. Earnings

Biomarin Pharmaceutical Inc.’s revenue jumped 14.84% since last year same period to $745.15Mn in the Q1 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 0.94% jump in its revenue since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit jumped 109.43% since last year same period to $185.69Mn in the Q1 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 48.62% jump in its net profits since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit margin jumped 82.36% since last year same period to 24.92% in the Q1 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 47.24% jump in its net profit margins since last 3-months.

Biomarin Pharmaceutical Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 21.3.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.83 - a 27.3% jump from last quarter’s estimates.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at 0.83.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q2 2025. This indicates that the Biomarin Pharmaceutical Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.